Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences

SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide a corporate overview of its clinical development and discovery programs at two upcoming investor conferences:

-- Natixis Bleichroeder Hidden Gems Conference

Presentation: Monday, October 8, 2007 at 8:00 a.m. Eastern Time (5:00

a.m. Pacific Time) at the Carlton Hotel on Madison Avenue in New York


Presenting: Robert E. Hoffman, Arena's Vice President, Finance and

Chief Financial Officer

-- BIO InvestorForum 2007

Presentation: Wednesday, October 10, 2007 at 2:15 p.m. Pacific Time

(5:15 p.m. Eastern Time) at the Palace Hotel in San Francisco

Presenting: Louis J. Scotti, Arena's Vice President, Marketing and

Business Development

A live audio webcast of each presentation will be available under the investor relations section of Arena's website at Replays of the presentations will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
(Date:10/13/2015)... -- PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.1035, ... average with 1,308,352 shares being traded. PMCB shares have been ... low of $.072 in September, then bouncing back to current ... due diligence will show investors in PharmaCyte Biotech, Inc. information ... using the link below at no cost. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... and assessment of organotypic 3D cell culture models, has launched a 14 ... in their patent-pending 3D InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... President. Steve joins as the Pistoia Alliance continues to drive to increase the ... non-profit Pistoia Alliance is focusing its vision and expanding its work in supporting ...
(Date:10/13/2015)... Oct. 13 2015 Research and Markets( ... & Europe Markets for Bone Morphogenetic Protein Growth Factor ... offering. --> --> ... the formation of bone after a fracture. In nature, ... in the formation of the skeleton. There are twenty ...
Breaking Biology Technology:
(Date:10/13/2015)... Feedzai , a data science company ... and minimize risk in the financial industry, announced a ... fraud prevention solution that gives merchants the ability to ... email address. The two companies will provide their mutual ... risk assessment with fraud risk scoring to streamline transaction ...
(Date:10/13/2015)... Dragon Capital Group Corp. (OTC: DRGV), a holding company ... announced today that its wholly owned subsidiary, Shanghai Yazheng Information ... Naked Eye 3D System for a period of one year. ... is expected to be completed in 2015. Management estimates the ... --> --> This Multi-Format Naked ...
(Date:10/13/2015)... DUBLIN , Oct. 7, 2015 Research ... of the "India Biometrics Authentication & Identification Market ... offering. --> --> ... from $823.46 million in 2014 to $2.06 billion in ... to 2020. India . ...
Breaking Biology News(10 mins):